THE USE OF INTRAVENOUS IMMUNOGLOBULIN PENTAGLOBIN IN THE COMPLEX TREATMENT OF SEVERE COMMUNITY-ACQUIRED PNEUMONIA IN CHILDREN
There are presented data from a comprehensive examination and treatment of 30 children with community-acquired pneumonia (CAP). For the treatment of young children with focal-confluent forms of CAP and the clinical manifestations of infectious-septic shock, Pentaglobin preparations containing IgM were used. Severe CAP with a tendency to destruction was more often observed in cases with the dominance of gram-negative flora in the etiological structure, most often detected in the foothill zone (18.2% of children), in the middle mountain zone - in- 13.3%, in the low-grade zone - in 5% of children. Pseudomonas aeruginosae was more commonly seeded in children in the foothill zone (12.5%), while in children living in the lowland and middle mountain zone in 2.5% and 6.6% correspondingly. The authors showed the preparation of intravenous immunoglobulin Pentoglobin is a safe, effective, easily tolerated means of etiotropic and pathogenetic therapy of severe CAP, caused more often by gram-negative and gram-positive bacterial microbiota.
About the authorsArslanova A.Yu.
Mizgerd JP. Pathogenesis of severe pneumonia: advances and knowledge gaps. Curr Opin Pulm Med. 2017; 23(3): 193-7.
Quinton LJ, Walkey AJ, Mizgerd JP. Integrative Physiology of Pneumonia. Physiol Rev. 2018; 98(3): 1417-64.
Lee KY. Pneumonia, Acute Respiratory Distress Syndrome, and Early Immune-Modulator Therapy. Int J Mol Sci. 2017; 18(2).doi: 10.3390/ijms18020388.
Smirnov I.E., Mityushin I.L., Kucherenko A.G., Bakradze M.D. Cytokine profile in bacterial and viral infections in children. Rossiyskiy pediatricheskiy zhurnal. 2014; 17 (4): 14-9. (in Russian)
Parakhonskiy A.P., Fedorovich O.K. Immune imbalance in children with pathology of the respiratory system of bacterial etiology. Uspekhi sovremennogo estestvoznaniya. 2009; 3:47-8. (in Russian)
Latysheva T.V. Principles of substitution therapy with intravenous immunoglobulins. Tsitokiny i vospalenie. 2005; 4(3): 58-62. (in Russian)
Antonov A.G., Antonova N.V., Biryukova T.V., Volodin N.N. Form for the use of immunoglobulin preparations for intravenous administration in neonatology. Voprosy prakticheskoy pediatrii. 2007; 2(2): 56-64. (in Russian)
Donyush E.K. Use of intravenous immunoglobulins in clinical practice. Voprosy sovremennoy pediatrii. 2011; 10(2): 49-63. (in Russian)
Egorova T.A., Khmelevskaya I.G. Comparative effectiveness of pharmacological immunomodulation Pentaglobin and likopida in preterm infants with bacterial disease in the neonatal period. Uspekhi sovremennogo estestvoznaniya. 2006; 8: 56-7. (in Russian)
Fedyaeva V.K., Rebrova Yu.A. A systematic review of the effectiveness of Pentaglobin in preventing all-cause mortality in bacterial infections and sepsis in children under two years of age. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2016; 3(1): 50-7. (in Russian)
Ehrenstein M.R., Notley C.A. The importance of natural IgM; scavenger, protector and regulator. Nature Reviews. 2010; 10: 778-86.
LaFon DC, Nahm MH. Measuring quantity and function of pneumococcal antibodies in immunoglobulin products. Transfusion. 2018; 58( Suppl 3): 3114-20.
Downing NS, McMullan CJ, Rennke HG, Levy BD, Loscalzo J. Complements from the Lung. N Engl J Med. 2018; 379(18): 1767-73.
Kuprina N.P., Kokoreva S.P., Cemenchenko L.V., Seredina E.Yu. The use of intravenous immunoglobulin “Pentaglobin” in the treatment of severe bacterial infections in children. Detskie infektsii. 2005; 4(3): 47-9. (in Russian)
Fesenko I.D. Rational application of human normal immunoglobulin for the intravenous induction. Pediatricheskaya farmakologiya. 2007; 4(1): 51-5. (in Russian)
Shestakova I.V., Yushchuk N.D. Modern drugs for treatment of viral and some bacterial infections. Infektsionnye bolezni. 2006; 4(1): 79-89. (in Russian)
Gerson JN, Ramamurthy C, Borghaei H. Managing adverse effects of immunotherapy. Clin Adv Hematol Oncol. 2018; 16(5): 364-74.
- Refbacks are not listed
Контент доступен под лицензией Creative Commons Attribution 3.0 License.